Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Abbott Park Road, Abbot Park ABBOTT PARK IL 60064-3500 |
Tel: | N/A |
Website: | https://www.abbott.com |
IR: | See website |
Key People | ||
Robert B. Ford Chairman of the Board, Chief Executive Officer | Randel W. Woodgrift Senior Vice President - Cardio Rhythm Management | Philip P. Boudreau Chief Financial Officer, Senior Vice President - Finance |
Robert E. Funck Executive Vice President - Finance | Hubert L. Allen Executive Vice President, General Counsel, Secretary | Mary K. Moreland Executive Vice President - Human Resources |
Lisa D. Earnhardt Executive Vice President, Group President - Medical Devices | Louis H. Morrone Executive Vice President - Core Diagnostics | Daniel Gesua Sive Salvadori Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products | Andrea Wainer Executive Vice President - Rapid and Molecular Diagnostics |
Business Overview |
Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products. |
Financial Overview |
For the fiscal year ended 31 December 2023, Abbott Laboratories revenues decreased 8% to $40.11B. Net income decreased 17% to $5.72B. Revenues reflect Diagnostics Products segment decrease of 40% to $9.99B, United States segment decrease of 15% to $15.45B, All other Countries segment decrease of 5% to $14.08B, Japan segment decrease of 22% to $1.51B. Net income also reflects Diagnostics Products segment income decrease of 64% to $2.43B. |
Employees: | 114,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $196,900M as of Dec 31, 2023 |
Annual revenue (TTM): | $40,109M as of Dec 31, 2023 |
EBITDA (TTM): | $9,965M as of Dec 31, 2023 |
Net annual income (TTM): | $5,723M as of Dec 31, 2023 |
Free cash flow (TTM): | $1,503M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $7,400M as of Dec 31, 2023 |
Shares outstanding: | 1,735,184,289 as of Jan 31, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |